Norwegian natural killer cell specialist Zelluna Immunotherapy has agreed terms for a new research collaboration, with Singapore-based Lion TCR.
Zelluna has been led by chief executive Namir Hassan, formerly of UK-based Immunocore, since late 2019.
The Oslo-based company will work with Lion on the development of T-cell receptor (TCR)-based natural killer cell therapies (TCR-NK) for virally induced cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze